Natera, Inc. (NASDAQ:NTRA) Position Boosted by Cwm LLC

Cwm LLC raised its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 41.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,867 shares of the medical research company’s stock after acquiring an additional 550 shares during the quarter. Cwm LLC’s holdings in Natera were worth $117,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Xponance Inc. grew its stake in shares of Natera by 1.8% in the 3rd quarter. Xponance Inc. now owns 14,506 shares of the medical research company’s stock valued at $642,000 after buying an additional 261 shares in the last quarter. Brown Advisory Inc. lifted its holdings in shares of Natera by 9.2% during the third quarter. Brown Advisory Inc. now owns 4,738 shares of the medical research company’s stock worth $210,000 after buying an additional 400 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Natera by 19.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,616 shares of the medical research company’s stock worth $912,000 after buying an additional 3,384 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Natera by 6.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 177,159 shares of the medical research company’s stock worth $7,839,000 after buying an additional 11,052 shares during the last quarter. Finally, ING Groep NV acquired a new position in shares of Natera during the third quarter worth approximately $1,491,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Transactions at Natera

In other news, insider Daniel Rabinowitz sold 35,307 shares of the company’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $75.09, for a total transaction of $2,651,202.63. Following the completion of the transaction, the insider now directly owns 204,218 shares of the company’s stock, valued at $15,334,729.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Daniel Rabinowitz sold 35,307 shares of the company’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $75.09, for a total transaction of $2,651,202.63. Following the completion of the transaction, the insider now directly owns 204,218 shares of the company’s stock, valued at $15,334,729.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jonathan Sheena sold 447 shares of the company’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $90.22, for a total value of $40,328.34. Following the transaction, the insider now directly owns 347,731 shares of the company’s stock, valued at $31,372,290.82. The disclosure for this sale can be found here. Insiders sold 380,750 shares of company stock valued at $31,864,820 over the last three months. Company insiders own 7.60% of the company’s stock.

Natera Trading Up 0.2 %

NASDAQ:NTRA opened at $97.21 on Tuesday. The business’s 50-day simple moving average is $91.02 and its 200-day simple moving average is $70.07. Natera, Inc. has a fifty-two week low of $36.90 and a fifty-two week high of $98.82. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. The stock has a market capitalization of $11.74 billion, a PE ratio of -25.65 and a beta of 1.38.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.09. The company had revenue of $311.11 million during the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. Sell-side analysts expect that Natera, Inc. will post -2.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Craig Hallum assumed coverage on Natera in a research note on Monday, April 8th. They issued a “buy” rating and a $117.00 target price for the company. Canaccord Genuity Group upped their target price on Natera from $87.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. The Goldman Sachs Group upped their target price on Natera from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, April 15th. StockNews.com upgraded Natera from a “sell” rating to a “hold” rating in a research note on Wednesday, May 1st. Finally, Raymond James lowered Natera from a “strong-buy” rating to an “outperform” rating and upped their target price for the company from $68.00 to $85.00 in a research note on Tuesday, February 20th. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $86.40.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.